Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Robot-assisted vs Laparoscopic Radical Prostatectomy for Prostate Cancer Treatment

12 juillet 2020 mis à jour par: Binh Dan Hospital
This study is to compare the outcomes of robotic-assisted laparoscopic radical prostatectomy (RARP) and laparoscopic radical prostatectomy (LRP) for prostate cancer treatment in terms of perioperative surgical, functional and oncological outcomes.

Aperçu de l'étude

Statut

Inconnue

Les conditions

Intervention / Traitement

Description détaillée

Participants will either have robotic-assisted laparoscopic radical prostatectomy (RARP) or laparoscopic radical prostatectomy (LRP) as determined by the treating surgeon. All participants will undergo tests and questionnaires to determine urinary and erectile function, biopsies to determine perioperative surgical, functional and oncological outcomes. These assessments will be conducted pre-operatively, post-operatively and at certain follow-up time points up to 12 months.

Type d'étude

Interventionnel

Inscription (Anticipé)

80

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • Viêt Nam
      • Ho Chi Minh City, Viêt Nam, 700000
        • Recrutement
        • Binh Dan Hospital
        • Contact:
          • Hoang PC Nguyen, Associate Professor, MD, PhD
          • Numéro de téléphone: +84 913 719 346
          • E-mail: npchoang@gmail.com

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Homme

La description

Inclusion Criteria:

  1. Adult men aged 18 years and over;
  2. Undergoing RARP or LRP. prostatectomy for prostate cancer at Binh Dan Hospital;
  3. Clinically suitable for radical prostatectomy (cT1-3, No, Mo);
  4. Cognitively able to give written informed consent for participation;
  5. Elective procedure.

Exclusion Criteria:

  1. The patient lacks the ability to consent for themselves;
  2. Patients unwilling to undergo pre- and post-operative evaluation according to the protocol;

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Robotic-assisted surgery
Procédure: Radical prostatectomy
The patients diagnosed with prostate cancer (local or locally advanced stages) will be allocated to the study for performing radical prostatectomy surgery.
Comparateur factice: Laparoscopic surgery
Procédure: Radical prostatectomy
The patients diagnosed with prostate cancer (local or locally advanced stages) will be allocated to the study for performing radical prostatectomy surgery.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
The console time
Délai: During the surgery
The time which surgeon spends on the robot console by minuite
During the surgery
Mean of blood loss
Délai: During the surgery
Milliliter
During the surgery
Perioperative transfusion rate (%)
Délai: Up to 1 month after operation
The number of cases which will be transfused.
Up to 1 month after operation
The rate of positive surgical margins, extracapsular extension, seminal vesicle invasion, (5)perineural invasion, the number of lymph node yield and node involvement,
Délai: Up to 1 week after operation
Number of cases, based on the result of pathology.
Up to 1 week after operation
Number of blood units transfused
Délai: Up to 1 week after operation
Milliliter
Up to 1 week after operation
the rate of conversion to open surgery, the rate of intraoperative incidents (%),
Délai: Up to 1 weeks after the surgery.
Percentage
Up to 1 weeks after the surgery.
The postoperative recovery parameters using Numeric Pain Rating Scale (NPRS),
Délai: Up to 3 month after surgery
The NPRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of pain, in a total of 10 points, higher score means worse, with 0 means no pain and 10 is the worst pain. The mean score will be calculated to reflect the post-operative pain.
Up to 3 month after surgery
Change of hemoglobin from baseline
Délai: Up to 1 week after operation
(mg/mL)
Up to 1 week after operation
The drainage time
Délai: Up to 3 months after surgery
(day),
Up to 3 months after surgery
To assess urethral catheter time, urethral catheter time
Délai: Up to 3 months after surgery
(day)
Up to 3 months after surgery
To assess bowel movement recovery time,
Délai: Up to 1 week after surgery
(day)
Up to 1 week after surgery
To assess postoperative hospital stay
Délai: Up to 1 month after surgery
(day)
Up to 1 month after surgery
The rate of postoperative complications (including infections)
Délai: in day 3, day 7, and 1 month after surgery.
Percentage
in day 3, day 7, and 1 month after surgery.
PSA level in blood
Délai: Before operation
(mg/mL)
Before operation
PSA level in blood
Délai: 6 weeks post-operation
(mg/mL)
6 weeks post-operation
PSA level in blood
Délai: 3 months post-operation
(mg/mL)
3 months post-operation
PSA level in blood
Délai: 6 months post-operation
(mg/mL)
6 months post-operation
PSA level in blood
Délai: 12 months post-operation
(mg/mL)
12 months post-operation
local and regional recurrences on sonography
Délai: through study completion, an average of 1 year
including ultrasound when PSA rising or any indication of recurrent
through study completion, an average of 1 year
local and regional recurrences, on MRI
Délai: through study completion, an average of 1 year
including MRI when PSA rising or any indication of recurrent
through study completion, an average of 1 year
local and regional recurrences, on PET Scan
Délai: through study completion, an average of 1 year
including PET Scan, when PSA rising or any indication of recurrent
through study completion, an average of 1 year

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Evaluating the pre and postoperative lower urinary tract symptoms using Full score of International Prostate Symptoms Scores (IPSS)
Délai: Preoperative
It contains seven questions related to symptoms related to BPH and one question related to the patient's perceived quality of life. The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points. The sum score will be calculated and the mean score will be evaluated.
Preoperative
Evaluating the pre and postoperative lower urinary tract symptoms using International Prostate Symptoms Scores (IPSS)
Délai: 3 months postoperative
It contains seven questions related to symptoms related to BPH and one question related to the patient's perceived quality of life. The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points. The sum score will be calculated and the mean score will be evaluated.
3 months postoperative
Evaluating the pre and postoperative lower urinary tract symptoms using Full score of International Prostate Symptoms Scores (IPSS)
Délai: 6 months, postoperative
It contains seven questions related to symptoms related to BPH and one question related to the patient's perceived quality of life. The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points. The sum score will be calculated and the mean score will be evaluated.
6 months, postoperative
Evaluating the pre and postoperative lower urinary tract symptoms using Full score of International Prostate Symptoms Scores (IPSS)
Délai: 12 months postoperative.
It contains seven questions related to symptoms related to BPH and one question related to the patient's perceived quality of life. The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points. The sum score will be calculated and the mean score will be evaluated.
12 months postoperative.
Erectile function assessments questionnaires and scoring using Index of Erectile Function Questionnaire, IIEF5, full score
Délai: Preoperative
The 15-question International Index of Erectile Function (IIEF) Questionnaire is a validated, multi-dimensional, self-administered investigation that has been found useful in the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials. A score of 0-5 is awarded to each of the 15 questions that examine the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction. The score ranges from 22 - 25 for Normal erectile function (no ED), 17 - 21 for Mild ED, 12 - 16 for Mild to moderate ED, 8 - 11 for Moderate ED, and from 1 - 7 for Severe ED (5 - 7, if a man had no opportunity to engage in sexual activity). The mean score will be calculated.
Preoperative
Erectile function assessments questionnaires and scoring using Index of Erectile Function Questionnaire, IIEF5, full score
Délai: 3 months, postoperative
The 15-question International Index of Erectile Function (IIEF) Questionnaire is a validated, multi-dimensional, self-administered investigation that has been found useful in the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials. A score of 0-5 is awarded to each of the 15 questions that examine the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction. The score ranges from 22 - 25 for Normal erectile function (no ED), 17 - 21 for Mild ED, 12 - 16 for Mild to moderate ED, 8 - 11 for Moderate ED, and from 1 - 7 for Severe ED (5 - 7, if a man had no opportunity to engage in sexual activity). The mean score will be calculated.
3 months, postoperative
Erectile function assessments questionnaires and scoring using Index of Erectile Function Questionnaire, IIEF5, full score
Délai: 6 months, postoperative.
The 15-question International Index of Erectile Function (IIEF) Questionnaire is a validated, multi-dimensional, self-administered investigation that has been found useful in the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials. A score of 0-5 is awarded to each of the 15 questions that examine the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction. The score ranges from 22 - 25 for Normal erectile function (no ED), 17 - 21 for Mild ED, 12 - 16 for Mild to moderate ED, 8 - 11 for Moderate ED, and from 1 - 7 for Severe ED (5 - 7, if a man had no opportunity to engage in sexual activity). The mean score will be calculated.
6 months, postoperative.
Erectile function assessments questionnaires and scoring using Index of Erectile Function Questionnaire, IIEF5, full score
Délai: 12 months postoperative
The 15-question International Index of Erectile Function (IIEF) Questionnaire is a validated, multi-dimensional, self-administered investigation that has been found useful in the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials. A score of 0-5 is awarded to each of the 15 questions that examine the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction. The score ranges from 22 - 25 for Normal erectile function (no ED), 17 - 21 for Mild ED, 12 - 16 for Mild to moderate ED, 8 - 11 for Moderate ED, and from 1 - 7 for Severe ED (5 - 7, if a man had no opportunity to engage in sexual activity). The mean score will be calculated.
12 months postoperative
The quality of life questionnaires and scoring using the the Short Form (36) Health Survey questionnaire
Délai: Preoperative
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. The mean score will be calculated.
Preoperative
The quality of life questionnaires and scoring using the the Short Form (36) Health Survey questionnaire
Délai: 3 months, postoperative.
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. The mean score will be calculated.
3 months, postoperative.
The quality of life questionnaires and scoring using the the Short Form (36) Health Survey questionnaire
Délai: 6 months, postoperative
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. The mean score will be calculated.
6 months, postoperative
The quality of life questionnaires and scoring using the the Short Form (36) Health Survey questionnaire
Délai: 12 months postoperative
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. The mean score will be calculated.
12 months postoperative

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Binh Dan Hospital

Les enquêteurs

  • Directeur d'études: Hung V Tran, MD, PhD, Binh Dan Hospital

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 janvier 2019

Achèvement primaire (Anticipé)

31 décembre 2020

Achèvement de l'étude (Anticipé)

31 décembre 2020

Dates d'inscription aux études

Première soumission

13 mai 2019

Première soumission répondant aux critères de contrôle qualité

4 juillet 2019

Première publication (Réel)

9 juillet 2019

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

14 juillet 2020

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 juillet 2020

Dernière vérification

1 juillet 2020

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • BD022019

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner